Skip to main content
OpenTrials
Completed

NCT Number: NCT04935463

Mucormycosis in COVID-19

The purpose is to allow phsyician reporters to contribute to MUNCO registry. Mucormycosis in COVID-19 is a rapidly escalating medical emergency reported in high numbers in India during the ongoing coronavirus surge. There is very little known about the risk factors, patterns and complications of mucormycosis as it occurs either during the infection or treatment phase of the novel coronavirus (COVID-19). In light of this emerging epidemic within a pandemic, it is of time sensitive importance to obtain a better understanding of the risk factors and outcomes of this fatal complication

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Diagnosed case of Mycotic Infection in COVID-19

Exclusion criteria

  • None

Treatment and study plan

Primary outcomes

  1. Vision loss

    Time frame: 60 days

Sponsors and collaborators

Lead sponsor

Montefiore Medical Center

Other

Collaborators

  • AIIMS Patna
  • HCG Oncology Bangalore
  • Medanta Institute Delhi
  • NSCB Jabalpur

Registry information

Acronym: MUNCO

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Jun 23, 2021
Registry last updated
Apr 18, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.